UCB Full Year Report 2020: UCB – sustaining growth, now and into the future
Brussels (ots/PRNewswire) - · Revenue increased to EUR 5.3 billion (+9%, +8% CER) net sales to EUR 5.1 billion (+8%, +7% CER)
· Underlying profitability (adj. EBITDA) was EUR 1.4 billion (+1%, -4% CER) or 27% of revenue
· R&D update: bimekizumab filed with FDA and EMA for psoriasis; timelines for late stage pipeline confirmed - despite pandemic
· Financial outlook for 2021: Revenue expected to reach EUR 5.45 -5.65 billion,
adjusted EBITDA 27 - 28% of revenue, Core EPS of EUR 5.60 -6.10 expected
· Outlook 2025:!-->…